Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines

Singh Gagandeep, Phyllis M. Novikoff, Michael Ott, Sanjeev Gupta

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Paclitaxel stabilizes microtubules with inhibition of mitotic spindle formation and has been found effective in several solid cancers. To test whether paclitaxel could be cytotoxic in human HCC cell lines, we used established HuH-7 and HepG2 cell lines. Changes in cell number, DNA synthesis rates and cell viability were determined. We tested whether paclitaxel-treated cells underwent apoptosis, microtubular reorganization, and cell cycle restriction. Studies also examined whether chemosensitization with verapamil enhanced the antitumor activity of paclitaxel. The cell viability was impaired at greater than 0.01 μM paclitaxel concentrations (LD50, 0.8 μM), with flow cytometry indicating accumulation of cells in G2/M, and immunostaining showing polymerized microtubules with characteristic banding patterns. This G2/M restriction was further characterized by flow cytometry, which revealed cyclin A and cdc2 kinase accumulation in paclitaxel-treated cells. Exposure to paclitaxel decreased [3H]thymidine incorporation into DNA in cells at 24 h but this significantly increased at 72 h, most likely due to DNA repair mechanisms related to cell cycle restriction. The cell death was via both apoptotic and non-apoptotic mechanisms. Finally, co-administration of the chemosensitizer verapamil in doses as little as 1 μM increased the antitumor efficacy of paclitaxel by up to five-fold and changed the LD50 of paclitaxel to 0.1 μM. The findings indicate that paclitaxel is cytotoxic to cultured hepatocellular carcinoma cells. Clinical studies of paclitaxel in patients with hepatocellular carcinoma may help determine additional therapies. Copyright (C) 1999.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalCancer Letters
Volume136
Issue number1
DOIs
StatePublished - Feb 8 1999

Fingerprint

Paclitaxel
Human Activities
Hepatocellular Carcinoma
Cell Line
Lethal Dose 50
Verapamil
Microtubules
Cell Survival
Cell Cycle
Flow Cytometry
Cyclin A
Spindle Apparatus
DNA
Hep G2 Cells
DNA Repair
Thymidine
Cell Death
Phosphotransferases
Cell Count
Apoptosis

Keywords

  • Carcinoma cells
  • Flow cytometry
  • Hepatocellular
  • Paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. / Gagandeep, Singh; Novikoff, Phyllis M.; Ott, Michael; Gupta, Sanjeev.

In: Cancer Letters, Vol. 136, No. 1, 08.02.1999, p. 109-118.

Research output: Contribution to journalArticle

Gagandeep, Singh ; Novikoff, Phyllis M. ; Ott, Michael ; Gupta, Sanjeev. / Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. In: Cancer Letters. 1999 ; Vol. 136, No. 1. pp. 109-118.
@article{92483cf4a0dd405bb963578d5d3df9cc,
title = "Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines",
abstract = "Paclitaxel stabilizes microtubules with inhibition of mitotic spindle formation and has been found effective in several solid cancers. To test whether paclitaxel could be cytotoxic in human HCC cell lines, we used established HuH-7 and HepG2 cell lines. Changes in cell number, DNA synthesis rates and cell viability were determined. We tested whether paclitaxel-treated cells underwent apoptosis, microtubular reorganization, and cell cycle restriction. Studies also examined whether chemosensitization with verapamil enhanced the antitumor activity of paclitaxel. The cell viability was impaired at greater than 0.01 μM paclitaxel concentrations (LD50, 0.8 μM), with flow cytometry indicating accumulation of cells in G2/M, and immunostaining showing polymerized microtubules with characteristic banding patterns. This G2/M restriction was further characterized by flow cytometry, which revealed cyclin A and cdc2 kinase accumulation in paclitaxel-treated cells. Exposure to paclitaxel decreased [3H]thymidine incorporation into DNA in cells at 24 h but this significantly increased at 72 h, most likely due to DNA repair mechanisms related to cell cycle restriction. The cell death was via both apoptotic and non-apoptotic mechanisms. Finally, co-administration of the chemosensitizer verapamil in doses as little as 1 μM increased the antitumor efficacy of paclitaxel by up to five-fold and changed the LD50 of paclitaxel to 0.1 μM. The findings indicate that paclitaxel is cytotoxic to cultured hepatocellular carcinoma cells. Clinical studies of paclitaxel in patients with hepatocellular carcinoma may help determine additional therapies. Copyright (C) 1999.",
keywords = "Carcinoma cells, Flow cytometry, Hepatocellular, Paclitaxel",
author = "Singh Gagandeep and Novikoff, {Phyllis M.} and Michael Ott and Sanjeev Gupta",
year = "1999",
month = "2",
day = "8",
doi = "10.1016/S0304-3835(98)00388-7",
language = "English (US)",
volume = "136",
pages = "109--118",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines

AU - Gagandeep, Singh

AU - Novikoff, Phyllis M.

AU - Ott, Michael

AU - Gupta, Sanjeev

PY - 1999/2/8

Y1 - 1999/2/8

N2 - Paclitaxel stabilizes microtubules with inhibition of mitotic spindle formation and has been found effective in several solid cancers. To test whether paclitaxel could be cytotoxic in human HCC cell lines, we used established HuH-7 and HepG2 cell lines. Changes in cell number, DNA synthesis rates and cell viability were determined. We tested whether paclitaxel-treated cells underwent apoptosis, microtubular reorganization, and cell cycle restriction. Studies also examined whether chemosensitization with verapamil enhanced the antitumor activity of paclitaxel. The cell viability was impaired at greater than 0.01 μM paclitaxel concentrations (LD50, 0.8 μM), with flow cytometry indicating accumulation of cells in G2/M, and immunostaining showing polymerized microtubules with characteristic banding patterns. This G2/M restriction was further characterized by flow cytometry, which revealed cyclin A and cdc2 kinase accumulation in paclitaxel-treated cells. Exposure to paclitaxel decreased [3H]thymidine incorporation into DNA in cells at 24 h but this significantly increased at 72 h, most likely due to DNA repair mechanisms related to cell cycle restriction. The cell death was via both apoptotic and non-apoptotic mechanisms. Finally, co-administration of the chemosensitizer verapamil in doses as little as 1 μM increased the antitumor efficacy of paclitaxel by up to five-fold and changed the LD50 of paclitaxel to 0.1 μM. The findings indicate that paclitaxel is cytotoxic to cultured hepatocellular carcinoma cells. Clinical studies of paclitaxel in patients with hepatocellular carcinoma may help determine additional therapies. Copyright (C) 1999.

AB - Paclitaxel stabilizes microtubules with inhibition of mitotic spindle formation and has been found effective in several solid cancers. To test whether paclitaxel could be cytotoxic in human HCC cell lines, we used established HuH-7 and HepG2 cell lines. Changes in cell number, DNA synthesis rates and cell viability were determined. We tested whether paclitaxel-treated cells underwent apoptosis, microtubular reorganization, and cell cycle restriction. Studies also examined whether chemosensitization with verapamil enhanced the antitumor activity of paclitaxel. The cell viability was impaired at greater than 0.01 μM paclitaxel concentrations (LD50, 0.8 μM), with flow cytometry indicating accumulation of cells in G2/M, and immunostaining showing polymerized microtubules with characteristic banding patterns. This G2/M restriction was further characterized by flow cytometry, which revealed cyclin A and cdc2 kinase accumulation in paclitaxel-treated cells. Exposure to paclitaxel decreased [3H]thymidine incorporation into DNA in cells at 24 h but this significantly increased at 72 h, most likely due to DNA repair mechanisms related to cell cycle restriction. The cell death was via both apoptotic and non-apoptotic mechanisms. Finally, co-administration of the chemosensitizer verapamil in doses as little as 1 μM increased the antitumor efficacy of paclitaxel by up to five-fold and changed the LD50 of paclitaxel to 0.1 μM. The findings indicate that paclitaxel is cytotoxic to cultured hepatocellular carcinoma cells. Clinical studies of paclitaxel in patients with hepatocellular carcinoma may help determine additional therapies. Copyright (C) 1999.

KW - Carcinoma cells

KW - Flow cytometry

KW - Hepatocellular

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0032996680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032996680&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(98)00388-7

DO - 10.1016/S0304-3835(98)00388-7

M3 - Article

C2 - 10211948

AN - SCOPUS:0032996680

VL - 136

SP - 109

EP - 118

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -